CHANGE OF CONTROL SEVERANCE AGREEMENTChange of Control Severance Agreement • March 9th, 2016 • XOMA Corp • Pharmaceutical preparations • California
This Change of Control Severance Agreement (the “Agreement”) dated this 3rd day of January, 2011 (the “Effective Date”), is between James R. Neal (the “Employee”) and XOMA Corporation, a Delaware corporation (the “Company”).
OFFICER EMPLOYMENT AGREEMENTOfficer Employment Agreement • March 9th, 2016 • XOMA Corp • Pharmaceutical preparations • California
This Officer Employment Agreement (“Agreement”), dated this 29th day of October, 2015, by and between XOMA (US) LLC (“XOMA” or the “Company”), a Delaware limited liability company with its principal office at 2910 Seventh Street, Berkeley, California, and James R. Neal (“Employee”), an individual residing at 875 El Cerro Blvd., Danville, California.
SETTLEMENT AND AMENDED LICENSE AGREEMENTSettlement and Amended License Agreement • March 9th, 2016 • XOMA Corp • Pharmaceutical preparations • New York
This Settlement and Amended License Agreement (“Agreement”), effective as of December 3, 2015 (the “Effective Date”), is entered into by and between XOMA (US) LLC (“XOMA”), a Delaware limited liability company having offices located at 2910 Seventh Street Berkeley, CA 94710, as successor-in-interest of XOMA Ireland Limited, and Pfizer Inc. (“PFIZER”), a Delaware corporation having offices located at 235 East 42nd Street, New York, NY 10017.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 9th, 2016 • XOMA Corp • Pharmaceutical preparations • New York
This Exclusive License Agreement (the “Agreement”) is entered into and made effective as of the First day of December, 2015 (the “Effective Date”) by and between XOMA (US) LLC, a limited liability company organized under the laws of Delaware having offices at 2910 Seventh Street, Berkeley, California, USA (“XOMA”), and Novo Nordisk A/S, a corporation organized under the laws of the Kingdom of Denmark (“Novo Nordisk”), having an address of Novo Alle, 2880 Bagsværd, Denmark, CVR No. 24 25 67 90. XOMA and Novo Nordisk are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractAsset Purchase Agreement • March 9th, 2016 • XOMA Corp • Pharmaceutical preparations • California
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
